(RTTNews) - The Commerce Department released a closely watched report on Wednesday showing consumer prices in the U.S. rose by slightly less than expected in the month of August.
(RTTNews) - On Wednesday, AEON Biopharma (AEON) said feedback from a Type 2b meeting with the U.S. Food and Drug Administration (FDA) provided further clarity on the development pathway for ABP-450 as a biosimilar to BOTOX.
(RTTNews) - Eli Lilly (LLY) said EBGLYSS (lebrikizumab-lbkz) met the primary and secondary endpoints in the Phase 3b ADtouch study, showing significant improvements in skin clearance, itch and pain among adults and adolescents with moderate-to-severe hand and foot atopic dermatit
(RTTNews) - Wednesday, AEON Biopharma (AEON) said FDA feedback from a Type 2b meeting provided clarity on the development pathway for ABP-450 as a biosimilar to BOTOX.
The NASDAQ 100 Pre-Market Indicator is up 110.77 to 30,450.1. The total Pre-Market volume is currently 145,772,447 shares traded.The following are the most active stocks for the pre-market session: Capricor Therapeutics, Inc. (CAPR) is +1.15 at $9.72, with 6,147,525 shares trade
(RTTNews) - On Wednesday, Satellos Bioscience (MSLE) said it has completed enrollment in BASECAMP, a Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD) in ambulatory boys aged 7 to 10 years.
(RTTNews) - Private sector employment in the U.S. jumped by more than expected in the month of September, according to a report released by payroll processor ADP on Wednesday.
(RTTNews) - Mattel, Inc. (MAT), a toy maker and entertainment company, said on Wednesday that its Chairman and Chief Executive Officer, Ynon Kreiz, will step down with effect from October 2 to take up a senior leadership role at another company.
(RTTNews) - Jade Biosciences, Inc. (JBIO) announced preclinical data for JADE301, an investigational, anti-IFN-Beta monoclonal antibody being developed for dermatomyositis, a rare autoimmune disease that can cause skin inflammation and muscle weakness.
(RTTNews) - Immunome, Inc. (IMNM), a clinical-stage targeted oncology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for treating
(RTTNews) - Rafael Holdings (RFL) reported topline results from the pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in patients with Niemann-Pick Disease Type C (NPC).